AMBUJACEM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | AMBUJACEM | Market Cap | 1,30,536 Cr. | Current Price | 528 ₹ | High / Low | 625 ₹ |
| Stock P/E | 36.4 | Book Value | 206 ₹ | Dividend Yield | 0.38 % | ROCE | 8.80 % |
| ROE | 8.77 % | Face Value | 2.00 ₹ | DMA 50 | 542 ₹ | DMA 200 | 556 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.23 % | PAT Qtr | 227 Cr. | PAT Prev Qtr | 1,571 Cr. |
| RSI | 47.1 | MACD | -8.77 | Volume | 32,99,155 | Avg Vol 1Wk | 34,88,092 |
| Low price | 455 ₹ | High price | 625 ₹ | PEG Ratio | 1.76 | Debt to equity | 0.02 |
| 52w Index | 43.1 % | Qtr Profit Var | -87.1 % | EPS | 13.7 ₹ | Industry PE | 30.6 |
📊 Financials: AMBUJACEM shows moderate fundamentals with ROCE at 8.80% and ROE at 8.77%, reflecting average capital efficiency. Quarterly PAT dropped sharply from ₹1,571 Cr. to ₹227 Cr., indicating significant earnings pressure. Debt-to-equity is very low at 0.02, highlighting a nearly debt-free balance sheet. EPS of ₹13.7 is modest relative to its large market cap of ₹1,30,536 Cr.
💹 Valuation: The stock trades at a P/E of 36.4, above the industry average of 30.6, suggesting mild overvaluation. P/B ratio is ~2.56 (528/206), which is reasonable compared to peers. PEG ratio of 1.76 indicates valuations are stretched relative to growth. Dividend yield of 0.38% provides limited income support.
🏢 Business Model & Competitive Advantage: AMBUJACEM operates in cement manufacturing, benefiting from strong brand recognition and infrastructure demand in India. Its competitive advantage lies in scale, distribution network, and efficient operations. However, profitability volatility and high input costs limit investor comfort.
📈 Entry Zone: Technicals show RSI at 47.1 (neutral) and MACD negative, with price below DMA 50 & 200. Accumulation may be considered near ₹455–500 for long-term investors. Current valuations are slightly stretched, so cautious entry is advised.
Positive
- Debt-to-equity ratio of 0.02 shows strong financial stability.
- Strong brand presence and wide distribution network.
- DII holdings increased by 0.23%, reflecting domestic institutional support.
Limitation
- ROCE (8.80%) and ROE (8.77%) are relatively weak.
- P/E ratio (36.4) above industry average (30.6).
- Dividend yield of 0.38% is modest.
Company Negative News
- Quarterly PAT dropped significantly (-87.1%), showing earnings weakness.
- FII holdings decreased by -0.11%, reflecting reduced foreign investor confidence.
- Stock trading below DMA 200, indicating weak momentum.
Company Positive News
- DII holdings increased (+0.23%), showing domestic institutional support.
- Strong trading volumes indicate investor interest.
Industry
- Cement industry benefits from infrastructure growth and housing demand.
- Industry P/E at 30.6 is lower than AMBUJACEM, showing sector-wide value opportunities.
- Government push for infrastructure projects supports long-term demand.
Conclusion
🔎 AMBUJACEM is financially stable with low debt and strong industry presence but faces weak profitability and stretched valuations. Entry near ₹455–500 may be considered for long-term investors. Conservative investors should wait for improved earnings visibility before committing to long-term holding.